This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nishihira, H. Articles by Nishi, T. Search for Related Content PubMed PubMed Citation Articles by Nishihira, H. Articles by Nishi, T. Social Bookmarking                            What's this?

Natural Course of Neuroblastoma Detected by Mass Screening: A 5-Year Prospective Study at a Single Institution

From the Divisions of Oncology, Pathology, Radiology, Hematology, and Surgery, Kanagawa Children’s Medical Center, Yokohama, Japan.

Address reprint requests to Yukichi Tanaka, MD, Division of Pathology, Kanagawa Children’s Medical Center, Mutsukawa 2–138-4, Minami-ku, Yokohama 232-8555, Japan; email p-cmck{at}gd5.so-net.ne.jp

PURPOSE: To describe various favorable courses of neuroblastoma (NBL) detected by mass screening and to present our observation program as a temporary treatment option, to be used until a final decision is made regarding the mass screening program for 6-month-old infants.

PATIENTS AND METHODS: Between October 1993 and November 1999, 26 of 51 patients with NBL detected by mass screening were enrolled in our observation program. The criteria for observation included urinary vanillylmandelic acid (VMA) and homovanillic acid (HVA) levels less than 50 µg/mg creatinine, smaller tumor size (< 5.0 cm), preoperative status, and granted informed consent. Patients were divided into four groups according to changes in urinary VMA and HVA values and tumor size. Patients who no longer fulfilled criteria underwent surgery.

RESULTS: The observation period ranged from 4 to 73 months. Urinary VMA and HVA levels decreased in 19 of 26 patients, often by age 16 months. Eighteen patients had regressing tumors, and in 10 of these cases, the tumor was undetectable or barely detectable by imaging techniques. Four patients younger than 12 months had increased tumor marker levels and tumor volume, histologically reflecting neuroblastic proliferation. The remaining three patients, all older than 18 months, had varied tumor marker levels but increased tumor volume, histologically reflecting an increase in Schwann cells. No upgrading of tumor stage or unfavorable biologic factor was noted in any patient.

CONCLUSION: None of our patients showed evidence of transition from favorable to unfavorable prognosis, a finding that points to a reduction in the significance of screening as a public health measure. Until results of ongoing screening trials involving older patients have been evaluated, the observation program can be used as a temporary measure to avoid, with little risk, unnecessary surgical intervention.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. Hero, T. Simon, R. Spitz, K. Ernestus, A. K. Gnekow, H.-G. Scheel-Walter, D. Schwabe, F. H. Schilling, G. Benz-Bohm, and F. Berthold Localized Infant Neuroblastomas Often Show Spontaneous Regression: Results of the Prospective Trials NB95-S and NB97 J. Clin. Oncol., March 20, 2008; 26(9): 1504 - 1510. [Abstract] [Full Text] [PDF]

				S. Barrette, M. L. Bernstein, J.-M. Leclerc, M. A. Champagne, Y. Samson, J. Brossard, and W. G. Woods Treatment Complications in Children Diagnosed With Neuroblastoma During a Screening Program J. Clin. Oncol., April 1, 2006; 24(10): 1542 - 1545. [Abstract] [Full Text] [PDF]

				W. M. Hsu, F. J. Hsieh, Y. M. Jeng, M. L. Kuo, C. N. Chen, D. M. Lai, L. J. Hsieh, B. T. Wang, P. N. Tsao, H. Lee, et al. Calreticulin expression in neuroblastoma--a novel independent prognostic factor Ann. Onc., February 1, 2005; 16(2): 314 - 321. [Abstract] [Full Text] [PDF]

				E. D. Tate, T. J. Allison, M. R. Pranzate, and S. J. Verhu Neuroepidemiologic Trends in 105 US Cases of Pediatric Opsoclonus-Myoclonus Syndrome Journal of Pediatric Oncology Nursing, January 1, 2005; 22(1): 8 - 19. [Abstract] [PDF]

				M. R. Pranzatelli, K. Hyland, E. D. Tate, L. A. Arnold, T. J. Allison, and G. S. Soori Evidence of Cellular Immune Activation in Children With Opsoclonus-Myoclonus: Cerebrospinal Fluid Neopterin J Child Neurol, December 1, 2004; 19(12): 919 - 924. [Abstract] [PDF]

				B. H. Kushner Neuroblastoma: A Disease Requiring a Multitude of Imaging Studies J. Nucl. Med., July 1, 2004; 45(7): 1172 - 1188. [Abstract] [Full Text] [PDF]

				C. Kitanaka, K. Kato, R. Ijiri, K. Sakurada, A. Tomiyama, K. Noguchi, Y. Nagashima, A. Nakagawara, T. Momoi, Y. Toyoda, et al. Increased Ras Expression and Caspase-Independent Neuroblastoma Cell Death: Possible Mechanism of Spontaneous Neuroblastoma Regression J Natl Cancer Inst, March 6, 2002; 94(5): 358 - 368. [Abstract] [Full Text] [PDF]